作者: Teja Kapoor , Joan Bathon
DOI: 10.1016/J.RDC.2018.06.008
关键词: Systemic inflammation 、 Tofacitinib 、 Methotrexate 、 Kidney disease 、 In patient 、 Rheumatoid arthritis 、 Adverse effect 、 Disease severity 、 Medicine 、 Internal medicine
摘要: Renal manifestations in rheumatoid arthritis (RA) have evolved as RA management has improved. In the past, older disease-modifying antirheumatic drugs, uncontrolled systemic inflammation, and chronic nonsteroidal antiinflammatory drug (NSAID) use contributed to kidney disease. Over time, of methotrexate biologic medications, decrease NSAID use, a treat-to-target strategy renal manifestations. Chronic disease now is more likely be caused by cardiovascular risk factors than severity. patients with dysfunction, NSAIDs, methotrexate, tofacitinib may need adjusted or avoided prevent adverse events.